Search results
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
Morningstar· 2 days agoEditas Medicine, Inc. (Nasdaq: EDIT), a clinical-stage gene editing company, today announced a two-year extension to the collaboration with Bristol Myers Squibb (NYSE: BMY) under which the parties ...
‘ChatGPT for CRISPR’ creates new gene-editing tools
Nature· 4 days agoSome of the AI-designed gene editors could be more versatile than those found in nature.
Dad’s microbiome can affect offspring’s health — in mice
Nature· 2 days agoHear the biggest stories from the world of science | 1 May 2024
iJAZ-based approach to engineer lepidopteran pest resistance in multiple crop species - Nature...
Nature· 4 days agoIn this study, Mo et al. describe a novel biotechnological strategy to produce crop plants resistant to lepidopteran pests.
How bioinformatics led one scientist home to Lithuania
Nature· 2 days agoJuozas Gordevičius founded a data-science company in the United States before returning to Vilnius.
Will Editas Medicine (EDIT) Report Negative Q1 Earnings? What You Should Know
Zacks via Yahoo Finance· 7 days agoEditas (EDIT) doesn't possess the right combination of the two key ingredients for a likely earnings...
USC Scientists Rewrite Kidney Research With Groundbreaking Cell Cultivation
SciTechDaily· 3 days agoResearchers at USC have advanced kidney research by developing a new method to cultivate nephron progenitor cells from human stem cells. This method simplifies the process and enhances applications ...
State of New Jersey Common Pension Fund D Has $2.48 Million Position in Intellia Therapeutics, Inc....
ETF DAILY NEWS· 17 hours agoState of New Jersey Common Pension Fund D raised its position in Intellia Therapeutics, Inc. (NASDAQ:NTLA – Free Report) by 26.6% during the 4th quarter, according to its most recent filing ...
Allspring Global Investments Holdings LLC Acquires Shares of 39,059 Caribou Biosciences, Inc....
ETF DAILY NEWS· 5 days agoAllspring Global Investments Holdings LLC purchased a new stake in Caribou Biosciences, Inc. (NASDAQ:CRBU – Free Report) in the 4th quarter, according to its most recent Form 13F filing with ...